Keyword: Tremfya (guselkumab)
Move over, Johnson & Johnson—AbbVie just joined the IL-23 party with a direct competitor to Tremfya, and analysts say it might just be best-in-class.
What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.
Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Sun Pharma debuts its first TV ad for psoriasis treatment Ilumya as national TV campaigns become table stakes in the crowded psoriasis category.
Johnson & Johnson’s Tremfya put a key rival on defense late last year with head-to-head data, and it’s keeping the heat on its competitors.
Competition and discounting are unsurprisingly taking a toll on J&J’s older drugs. But cardiovascular product Xarelto is also on that list.
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.
Johnson & Johnson’s Tremfya may have debuted behind Novartis' Cosentyx, but it has now topped the blockbuster in a head-to-head trial.
Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.